Gary Fegel
Founder @ GMF Capital
Zürich, Switzerland
Gary Fegel is a seed investor at GMF Capital in Zürich focused on Bitcoin and Security. Gary Fegel - Founder @ GMF Capital
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Gary Fegel invests in
Stages Gary Fegel invests in
Countries Gary Fegel invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Bitcoin 1 (33%)
- Security 1 (33%)
- Biometrics 1 (33%)
- Health Care 1 (33%)
- Therapeutics 1 (33%)
Stage
- Seed 1 (33%)
- Post-IPO Equity 1 (33%)
- Venture - Series Unknown 1 (33%)
Country
- United States 2 (67%)
- Israel 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| sMiles is a platform for micropayments and micro-incentives in Bitcoin. | Seed / Feb 10, 2022 | ||
| InterCure is a medical device company that has developed and patented a technology platform for respiratory-based treatment of cardiovascular and pulmonary diseases.The Company has incorporated its "Interactive Respiratory-Pacing" technology platform into several product lines, the first two of which offer a new therapeutic class ofnon-drug treatments for two of the most widespread and costly disease states in the healthcare industry: hypertension and heart failure.InterCure’s first market-ready product, RESPeRATE, is the only FDA-cleared, medical device clinically proven to lower high blood pressure with no side effects.InterCure's heart failure product, InTone™ has successfully completed phase 2a efficacy clinical trials and is expected to be launched when it completes the regulatory approval process.With its outstanding management team, the board of directors and a world-class Scientific Advisory Board, Intercure is poised to become the market leader in patient-focused medical devices that provide non-drug, no-side-effect treatment for some of the world's most prevalent and costly chronic conditions.InterCure was founded in 1994 and is headquartered in Ra'anana, Israel. | $17.5M / Post-IPO Equity / Nov 01, 2018 | ||
| FST's unique identification technology offers a seamless access experience. IMID Access software with In Motion Identification technology quickly and accurately identifies users at a distance and in motion. | $15M / Venture - Series Unknown / May 11, 2015 |
Co-Investors
GMG Capital Partners
1 deal together
Goodwater Capital
1 deal together
About GMF Capital
GMF Capital is a private investment vehicle that engages in private equity and alternative investments across a broad range of asset classes including real estate, healthcare, and structured credit. The management platform's investment approach is driven by its experience and a proprietary network of relationships. It generates outsizerisk-adjusted returns through cash-flowing investments characterized by liquidity and limited exposure to cyclical volatility.GMF Capital began its operations in 2013 and is operating in New York.
GMF Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Gary Fegel
Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Gary Fegel invest in?
Gary Fegel invests primarily in Bitcoin, Security and Biometrics startups, most often at Seed and Post-IPO Equity stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Gary Fegel?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gary Fegel last invest?
The most recent investment recorded for Gary Fegel closed in Feb 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
